Template:Side effects of estramustine phosphate (EMC)

v
t
e
Side effects of estramustine phosphate (EMC)
System organ class	Very common (≥10%)	Common (1–10%)	Frequency unknown^c
Blood and lymphatic system disorders	Anemia; Leukopenia	Thrombocytopenia
Immune system disorders			Hypersensitivity
Metabolism and nutrition disorders	Fluid retention
Psychiatric disorders			Confusional state; Depression
Nervous system disorders		Lethargy; Headache
Cardiac disorders	Congestive heart failure	Myocardial infarction	Myocardial ischemia
Vascular disorders		Embolism	Hypertension
Gastrointestinal disorders	Nausea^b; Vomiting^b; Diarrhea^b
Hepatobiliary disorders	Abnormal hepatic function
Skin and subcutaneous tissue disorders			Angioedema^c; Allergic dermatitis
Musculoskeletal and connective tissue disorders			Muscle weakness
Reproductive system and breast disorders	Gynecomastia		Erectile dysfunction
General disorders and administration site conditions			Injection site thrombosis (IVTooltip intravenous solution)
Footnotes: ^a = Could not be estimated from available data. ^b = Especially during the first 2 weeks of therapy. ^c = Angioedema (Quincke edema, larynx edema) can occur. Often occurs in combination with ACE inhibitors. EMP should be immediately discontinued if angioedema occurs. Sources: ^[1]

References

^ "Estracyt Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Pfizer Limited. 12 August 2013. Retrieved 8 February 2014.